StreetAlpha.app
Home › Stocks › BBOT

BridgeBio Oncology Therapeutics, Inc. (BBOT)

$1.94
▼ −2.02%
LAST CLOSE · NOV 17

BridgeBio Oncology Therapeutics develops oral cancer drug candidates that target KRAS and PI3Kα signaling. It last closed at $1.94 on Nov 17, down 2.02% on the day. The average 12-month price target from 9 analysts is $17.78 (+816.4% from the last close), with a high of $27.00 and a low of $9.00. Analyst consensus is Strong Buy, based on the latest ratings from 9 firms (9 buy, 0 hold, 0 sell).

AI Auto Pilots
Is BBOT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$171.5M
Free cash flow
−$151.0M
Valuation
Market cap
$155.7M
80.3M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$76.5M
At Sep 30
Shareholder equity
$293.4M
Shares outstanding
80.3M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: −$42K−$42KFY2023FY2024: −$74.3M−$74.3MFY2024FY2025: −$134.0M−$134.0MFY2025

From BBOT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 9 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
9firms
9 Buy0 Hold0 Sell
Each firm's latest rating on BBOT in the past 90 days
Average 12-month target
$17.78
▲ 816.4% upside

Based on 9 analysts who set a price target on BBOT in the past 90 days. The average target is $17.78, with a high of $27.00 and a low of $9.00, compared with the last close of $1.94.

Low $9.00Avg $17.78High $27.00
Blue marker: last close $1.94
Highest target$27.00
Average target$17.78
Lowest target$9.00
Latest rating changes
Piper SandlerMaintained
Nov 11Buy$15
WedbushTarget lowered
Nov 11Buy$25 → $9
Morgan StanleyMaintained
Oct 21Buy$13
OppenheimerTarget lowered
Oct 20Buy$22 → $16
JP MorganTarget lowered
Sep 11Buy$25 → $23
DateFirmActionRatingPrice target
Nov 11Piper SandlerMaintainedBuy$15
Nov 11WedbushTarget loweredBuy$25 → $9
Oct 21Morgan StanleyMaintainedBuy$13
Oct 20OppenheimerTarget loweredBuy$22 → $16
Sep 11JP MorganTarget loweredBuy$25 → $23
Loading…

Technical Analysis

BBOT · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 24% below its 20 day and 74% below its 50 day average. It is 289% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), oversold. The nearest support is the 52 week low at $1.93, and the nearest resistance the Pivot at $1.98.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 14.1%/day
Key levels
$14.8752 week high+666.5%
$7.54200 day average+288.7%
$6.06100 day average+212.4%
$3.3750 day average+73.7%
$2.68Swing high (Nov 12)+38.1%
$2.4120 day average+24.2%
$2.03Pivot R1+4.6%
$1.98Pivot+2.1%
$1.94Last close
$1.9352 week low−0.5%
$1.89Pivot S1−2.6%
Indicators
RSI (14)29.60Oversold below 30Oversold
MACD-0.43Above its signal lineBullish
Stochastic5.7Near the bottom of its rangeOversold
ADX (14)50.2Strong downtrend
Williams %R-99.0Oversold below −80, overbought above −20Oversold
CCI (20)-129.1Oversold below −100, overbought above 100Oversold
Rate of change−16.4%Change over 10 sessionsBearish
ATR (14)$0.27Typical daily range, 14.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BBOT

What happened before

See how BBOT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in BBOT in the last 90 days.

Loading…

See today’s whale options flow across the market →

BBOT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲56 buying vs 29 selling
  • ▲Held by funds +1.4 pts
  • ▲Funds holding +23
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8966+34.8%
In funds' top 1054+25.0%
Held by funds75.1%73.7%+1.4 pts
New / increased33 / 2317 / 21+47.4%
Reduced / sold out20 / 915 / 18−12.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BBOT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BBOT is in one of them and how their past BBOT trades turned out.

BBOT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BBOT in an article yet. Here's the latest on the wider market.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics is a biotechnology company based in South San Francisco, California, that is developing oral small molecule drugs for cancer. Its pipeline targets KRAS, a protein that is mutated in many cancers, and PI3Kα, a signaling protein that RAS proteins activate. The company is designing its drug candidates for patients with lung, breast, pancreatic and colorectal cancers, and it is testing them in early stage clinical trials.

Headquarters
South San Francisco, CA